BioSpace News Archive

The report provides details about market size, market restraints, drivers, challenges, growth opportunities, and top companies in the market. The report also highlights about changes in the market dynamics due to outbreak of the COVID-19 pandemic.

NovaSignal Corp., today announced the results of a multi-center, prospective, single-arm study which show the autonomous NovaGuide™ Intelligent Ultrasound is three times more likely to detect right-to-left shunt (RLS) – a recognized risk factor for stroke – than standard of care transthoracic echocardiography (TTE).

The U.S. Food and Drug Administration has been notified by Pfizer that new data have recently emerged regarding its emergency use authorization request for the use of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age.

AbCellera (Nasdaq: ABCL) today announced that bebtelovimab (LY-CoV1404), the second antibody developed through AbCellera’s collaboration with Eli Lilly and Company (Lilly), has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA).

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2021 financial results on Thursday, February 24, 2022, after the market close.

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022, at 12:40 p.m. Pacific Time.

MaxCyte, Inc. announced that, on February 10, 2022, the Compensation Committee of MaxCyte’s Board of Directors granted stock options to purchase an aggregate of 204,500 shares of MaxCyte’s common stock to eight newly hired employees.

The United States Pathology and Laboratory Society Leadership has endorsed the National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) Joint Task Force recommendation to use a new race-free equation to diagnose kidney diseases, also known as chronic kidney disease.

Ortho Regenerative Technologies Inc., a clinical-stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced a non-brokered private placement of units for maximum gross proceeds of $3.0 million.

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced 12-month data from the SENZA-NSRBP randomized controlled trial (RCT) was published online in Journal of Neurosurgery: Spine.